Loading clinical trials...

Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma | Clinical Trials | Clareo Health

TERMINATEDPHASE1

Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma

A Phase I Clinical Trial of Radiolabeled Immunotherapy With Humanized LL2 in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

NCT00054834•Gilead Sciences

View on ClinicalTrials.gov

Summary

The purpose of this trial is to determine the safety of 90Y-hLL2 at different dose levels in the treatment of Non-Hodgkin's lymphoma.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Disease Characteristics:
•Patients with a documented histologic or cytologic diagnosis of B-cell NHL.
•Age Range: Male or Female at least 18 years of age
•Performance Status: Patients with a Karnofsky performance status \> 60% (or equivalent, ECOG 0-2) and expected survival of at least 12 weeks.
•Hematopoietic: Hemoglobin \> 10 g/dL; ANC \> 1.5x10\^9/L; Platelets \> 100x10\^9/L;
•Hepatic: Serum bilirubin \< 2.0 mg/dL; AST and ALT \< 2 x ULN w/o liver metastases or \<5 x ULN w/liver metastases
•Renal: Creatinine \< 2.0 mg/dL
•Cardiovascular: Patients with LVEF \>/= 50% by MUGA or 2D-ECHO.
•Pulmonary: Patients with DFCO and FEV1 \>/= 60% by required Pulmonary Function Tests.
•Other: Patients agreeing to use a medically effective method of contraception while enrolled in the study. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the study. Patients able to understand and give written informed consent.

Exclusion Criteria

•Patients with at least one measurable tumor site \> 1.5 cm in at least one dimension.
•Prior/Concurrent Therapy:
•Biologic Therapy: Patients who have received human or humanized monoclonal antibodies will be eligible provided pre-study evaluations demonstrate no significant reactivity with hLL2 IgG (i.e., HAHA).

Locations (2)

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

MD Anderson Cancer Center

Houston, Texas, United States

Key Dates

Start Date

March 1, 2003

Last Updated

August 16, 2021

Enrollment

Estimated participants

Conditions

Non-Hodgkins Lymphoma

Interventions

hLL2 (epratuzumab)

DRUG

Resiliency in Older Adults Undergoing Bone Marrow Transplant

NCT04188678

LeukemiaLymphoma+4 more

View study

COMPLETEDPHASE2

Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.

NCT00739141

LeukemiaMyelodysplastic Syndrome+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 16, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma

Inclusion Criteria

Exclusion Criteria

Resiliency in Older Adults Undergoing Bone Marrow Transplant

Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation

Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma